Physician profile
Amita R Patel
NPI 1649265489
$2,130,861.26
in general payments reported to CMS, 2019-2025
22 companies · $490K in 2025
The $490K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240K · 2020: $68K · 2021: $193K · 2022: $223K · 2023: $413K · 2024: $504K · 2025: $490K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.0M · Consulting Fee: $200K · Travel and Lodging: $166K · Food and Beverage: $27K · Honoraria: $7,088 · Education: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,005,588.29 |
| Consulting Fee | $200,402.00 |
| Travel and Lodging | $166,350.78 |
| Food and Beverage | $27,367.96 |
| Honoraria | $7,088.00 |
| Education | $347.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $700,182.54 | 2019-2025 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $460,958.68 | 2023-2025 | Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $384,357.45 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Avanir Pharmaceuticals, INC. | $309,459.12 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $138,995.25 | 2019-2025 | Nuplazid |
| E.R. Squibb & Sons, L.L.C. | $112,246.18 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $16,605.10 | 2023-2025 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $5,590.16 | 2022-2025 | Rexulti, Nuedexta |
| Biogen, INC. | $1,740.00 | 2021 | |
| Eisai INC. | $161.06 | 2021-2024 | |
| Alkermes, INC. | $140.84 | 2019-2022 | |
| Abbvie INC. | $75.80 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $75.01 | 2022 | |
| Lilly USA, LLC | $74.12 | 2019 | |
| Idorsia Pharmaceuticals US INC | $57.80 | 2023 | Quviviq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $26.52 | 2019 | |
| Vanda Pharmaceuticals INC. | $21.31 | 2019 | |
| Livanova USA, INC. | $20.94 | 2020 | |
| Noven Therapeutics, LLC | $20.24 | 2020 | |
| Neurelis, INC. | $17.97 | 2024 | Valtoco |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.88 | 2021 | |
| Ironshore Pharmaceuticals INC. | $17.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amita Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.